Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Respiratory effects of treatment with a glucagon-like peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease
Metabolic effects beyond weight loss Both cagrilintide and retatrutide affect metabolic parameters far beyond the number on the scale
6.1 3.9 pM, P 0.05, n = 68
Finally, GLP-1s slow down digestion, changing the way a person's body turns food into energy
(Assessment Criteria) EBOO therapy offers particular promise for specific patient profiles
F., & Aberer, W
US$ 20.16
US$ 22.78
US$ 27.10
